BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34622876)

  • 1. Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma.
    Liao C; Wang A; Ma Y; Liu H
    Medicine (Baltimore); 2021 Oct; 100(40):e27473. PubMed ID: 34622876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bioinformatics analysis of the association between long non-coding RNA ubiquitin-specific peptidase 30 antisense RNA 1 (lncRNA USP30-AS1) and immune cell infiltration in ovarian serous cystadenocarcinoma].
    Wang H; Huang S; Meng Q; Zhang J; Wei L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Sep; 39(9):834-840. PubMed ID: 37732580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis.
    Liu H; Wang A; Ma Y
    Biomed Res Int; 2020; 2020():1392674. PubMed ID: 33299855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
    Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
    Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.
    Chen B; Lu X; Zhou Q; Chen Q; Zhu S; Li G; Liu H
    PLoS One; 2023; 18(8):e0290031. PubMed ID: 37582104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical prognostic value of lncRNA FOXP4-AS1 in cancer patients: A meta-analysis and bioinformatics analysis based on TCGA datasets.
    Shu Q; Liu X; Yang J; Mou T; Xie F
    Medicine (Baltimore); 2022 Oct; 101(42):e31439. PubMed ID: 36281152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
    Leonard B; Starrett GJ; Maurer MJ; Oberg AL; Van Bockstal M; Van Dorpe J; De Wever O; Helleman J; Sieuwerts AM; Berns EM; Martens JW; Anderson BD; Brown WL; Kalli KR; Kaufmann SH; Harris RS
    Clin Cancer Res; 2016 Sep; 22(18):4746-55. PubMed ID: 27016308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXP4-AS1 is a favorable prognostic-related enhancer RNA in ovarian cancer.
    Hua T; Tian YJ; Wang RM; Zhao CF; Kong YH; Tian RQ; Wang W; Ma LX
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33870423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DDX59-AS1 is a prognostic biomarker and correlated with immune infiltrates in OSCC.
    Sun Y; Zhou Q; Sun J; Bi W; Li R; Wu X; Li N; Song L; Yang F; Yu Y
    Front Genet; 2022; 13():892727. PubMed ID: 36081993
    [No Abstract]   [Full Text] [Related]  

  • 12. Long Non-coding RNA
    Yim GW; Kim HJ; Kim LK; Kim SW; Kim S; Nam EJ; Kim YT
    Cancer Res Treat; 2017 Jul; 49(3):656-668. PubMed ID: 27737536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study.
    Liu R; Hu R; Zeng Y; Zhang W; Zhou HH
    EBioMedicine; 2020 Jan; 51():102602. PubMed ID: 31911269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA FOXP4-AS1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer.
    Li J; Lian Y; Yan C; Cai Z; Ding J; Ma Z; Peng P; Wang K
    Cell Prolif; 2017 Feb; 50(1):. PubMed ID: 27790757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HTRA3 Is a Prognostic Biomarker and Associated With Immune Infiltrates in Gastric Cancer.
    Ji C; Sun LS; Xing F; Niu N; Gao HL; Dai JW; Zhou N; Jiang BC
    Front Oncol; 2020; 10():603480. PubMed ID: 33425760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Non-Coding RNA HAND2-AS1 Acts as a Tumor Suppressor in High-Grade Serous Ovarian Carcinoma.
    Gokulnath P; de Cristofaro T; Manipur I; Di Palma T; Soriano AA; Guarracino MR; Zannini M
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NLRP12 is a prognostic biomarker and correlated with immune infiltrates in epithelial ovarian cancer.
    Ma R; Tang Z; Wang J
    J Gene Med; 2024 Jan; 26(1):e3585. PubMed ID: 37926491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.
    Zhan F; Guo Y; He L
    J Ovarian Res; 2024 Apr; 17(1):92. PubMed ID: 38685095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.